SCHEMBL6786617

SCHEMBL6786617

CCCCCCN(C)c1ccc(/C=C2\SC(=S)N(CCNC(=O)C(F)(F)F)C2=O)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MCHR1 Q99705 1/20 0.45
▸ MAPT P10636 4/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ FFAR1 O14842 1/20 0.44
▸ MYC P01106 1/20 0.44
▸ MAX P61244 1/20 0.44
▸ MAOA P21397 1/20 0.44
▸ MAOB P27338 1/20 0.44
▸ PAX8 Q06710 1/20 0.43
▸ DNM1 Q05193 1/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ NCOA3 Q9Y6Q9 2/20 0.42
▸ MITF O75030 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6786621 1.00 MCHR1 (0.45) MCHR1MAPTALDH1A1MAPK1FFAR1
SCHEMBL6792827 0.90 MYC (0.50) MCHR1MAPTALDH1A1MAPK1FFAR1
SCHEMBL6792830 0.90 MYC (0.50) MCHR1MAPTALDH1A1MAPK1FFAR1
SCHEMBL6790713 0.89 MCHR1 (0.43) MCHR1MAPTALDH1A1MAPK1FFAR1
SCHEMBL6790715 0.89 MCHR1 (0.43) MCHR1MAPTALDH1A1MAPK1FFAR1
SCHEMBL6903986 0.85 ALDH1A1 (0.44) MCHR1MAPTALDH1A1MAPK1FFAR1
SCHEMBL7060689 0.85 ALDH1A1 (0.44) MCHR1MAPTALDH1A1MAPK1FFAR1
SCHEMBL7486833 0.83 CISD1 (0.62) MAPTALDH1A1FFAR1MYCMAX
SCHEMBL7486836 0.83 CISD1 (0.62) MAPTALDH1A1FFAR1MYCMAX
SCHEMBL6785606 0.82 ALDH1A1 (0.47) MCHR1MAPTALDH1A1MAPK1FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1192144-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2002-04-03 — — EP claimed
WO-2000076988-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2000-12-21 — — WO claimed
US-20040197268-A1 Method of imaging amyloid deposits using substituted rhodanine derivatives AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-10-07 — — US disclosed
EP-1192144-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2002-04-03 — — EP disclosed
WO-2000076988-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2000-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040197268-A1 Method of imaging amyloid deposits using substituted rhodanine derivatives APP, PSEN1, PSEN2 MCHR1 551/4885MAPT 5/4885ALDH1A1 1741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback